billHR4710Event Wednesday, July 23, 2025Analyzed

No Surprises Act Enforcement Act

Bearish

Summary

The No Surprises Act Enforcement Act (HR4710) is an early-stage House bill that would increase balance billing penalties from $100/day to $10,000 per violation for health insurers. The bill has been referred to three committees and has a Senate companion (S2420). Despite the bearish legislative signal, major insurers including ELV (+7.71% 7-day) and HUM (+13.29% 7-day) have shown strong recent price momentum driven by other factors.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR4710 increases balance billing penalties 100x, from $100/day to $10,000 per violation
  • 2.Bill is early stage (referred to 3 committees) with Senate companion; long path to enactment
  • 3.All five major insurers show strong recent price gains despite this bearish regulatory signal
  • 4.No government spending authorized — pure regulatory cost increase for insurers

Market Implications

The disconnect between the bearish legislative signal and strong stock performance for insurers ($UNH, $ELV, $CI, $HUM, $CVS) suggests the market is pricing this bill as low-probability or low-impact in the near term. Health insurer stocks have rallied 15-40% over the past 30 days, likely driven by factors such as Medicare Advantage rate finalizations or earnings beats. Investors should monitor committee assignments and hearings for signals of legislative acceleration. If the bill advances past committee markup, expect a 1-3% sector-wide pullback on increased regulatory risk premium. For now, the market is treating this as noise.

Full Analysis

HR4710, the No Surprises Act Enforcement Act, was introduced on July 23, 2025 by Rep. Murphy (R-NC-3) with 26 cosponsors. The bill amends the Public Health Service Act, ERISA, and the Internal Revenue Code to increase penalties for balance billing violations from $100 per day to $10,000 per individual failure. The bill is in early stage — referred to the Committees on Energy and Commerce, Education and Workforce, and Ways and Means. A companion bill (S2420) exists in the Senate.

The bill does not authorize or appropriate any funding; it is a regulatory penalty increase with zero direct government spending. The money trail works through increased compliance costs and penalty exposure for health insurers that would be forced to pay higher fines for violations of existing balance billing protections. The mechanism is purely punitive — a cost increase for obligated parties (group health plans and insurers) with no offsetting revenue or subsidy.

Structural losers are major health insurers: UnitedHealth Group ($UNH), Elevance Health ($ELV), Cigna Group ($CI), Humana ($HUM), and CVS Health ($CVS) via its Aetna subsidiary. These companies face a 100x increase in per-violation penalties, creating a new regulatory cost layer. The bill's early stage and bipartisan sponsorship (Republican lead, multiple Democratic cosponsors) suggest it has moderate legislative momentum but a long path to enactment.

Real market data shows the opposite of what this bill would suggest: insurers have rallied sharply. ELV is at $371.34 (+7.71% 7-day, +26.84% 30-day), HUM at $243.84 (+13.29% 7-day, +40.63% 30-day), UNH at $366.68 (+3.31% 7-day, +35.51% 30-day), CVS at $83.05 (+6.54% 7-day, +15.62% 30-day), and CI at $284.66 (+3.27% 7-day, +6.71% 30-day). This rally is likely driven by other catalysts (earnings, Medicare Advantage rate updates) overwhelming the distant regulatory risk.

Timeline: The bill must pass through three House committees before a floor vote, then reconcile with S2420. Given the current early stage with no committee hearings or markups, enactment in the 119th Congress (2025-2027) is uncertain. Real impact on insurer earnings is likely 2-3 years out even if passed.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Strong

Multiple independent sources confirm this signal’s market thesis

Confirmed by:
$$UNH▼ Bearish
Est. $50.0M$200.0M revenue impact

What the bill does

Increased civil penalty from $100/day to $10,000 per failure for balance billing violations under PHSA, ERISA, and IRC amendments

Who must act

Group health plans and health insurance issuers, including UnitedHealthcare (a segment of UnitedHealth Group)

What happens

Maximum penalty per violation rises from $100 per day to $10,000 per failure, representing a 100x increase in per-incident liability

Stock impact

UnitedHealthcare's insurance segment faces materially higher regulatory compliance costs and financial risk for any future balance billing errors; estimated annual compliance and legal exposure increase of $50M-$200M depending on audit frequency

$$ELV▼ Bearish
Est. $30.0M$120.0M revenue impact

What the bill does

Increased civil penalty from $100/day to $10,000 per failure for balance billing violations under PHSA, ERISA, and IRC amendments

Who must act

Group health plans and health insurance issuers, including Elevance Health

What happens

Maximum penalty per violation rises from $100 per day to $10,000 per failure, representing a 100x increase in per-incident liability

Stock impact

Elevance's commercial health plan segment faces higher penalty exposure; as a large national insurer, estimated compliance cost increase of $30M-$120M annually

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.